StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a research note released on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Performance
Shares of NASDAQ AEZS opened at $3.73 on Monday. The business’s 50-day simple moving average is $4.61 and its 200-day simple moving average is $6.27. Aeterna Zentaris has a 52 week low of $3.96 and a 52 week high of $12.00. The firm has a market cap of $6.68 million, a price-to-earnings ratio of -0.25 and a beta of 1.55.
About Aeterna Zentaris
Further Reading
- Five stocks we like better than Aeterna Zentaris
- What Investors Need to Know to Beat the Market
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What is a buyback in stocks? A comprehensive guide for investors
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.